The concept of immunocompromised district might explain the carcinogenic progression in hidradenitis suppurativa

Acta Oncologica

Volumn 56, Issue 10, 2017, Pages 1330-1331

  De Vita, Valerio ^a   Ruocco, Eleonora ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; CARCINOGEN;

BUTTOCK; CANCER PATIENT; EXTRACELLULAR FLUID; GLUTEUS MUSCLE; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; LETTER; LIFESPAN; LYMPHATIC DRAINAGE; LYMPHEDEMA; MALIGNANT NEOPLASM; PRIORITY JOURNAL; SKIN; SKIN CARCINOGENESIS; SKIN CARCINOMA; SUPPURATIVE HIDRADENITIS; TUMOR IMMUNITY; TUMOR LOCALIZATION; CARCINOGENESIS; DISEASE EXACERBATION;

CARCINOGENESIS; CARCINOGENS; DISEASE PROGRESSION; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNOCOMPROMISED HOST;

EID: 85019235421     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/0284186X.2017.1324214     Document Type: Letter

References (19)

1. Zhang LQ, Tan C., Squamous cell carcinoma arising in chronic hidradenitis suppurativa: a lethal complication to be avoided. Acta Oncol. 2017;56:497–498.
2. Cosman BC, O’grady TC, Pekarske S., Verrucous carcinoma arising in hidradenitis suppurativa. Int J Colorectal Dis. 2000;15:342–344.
3. Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology (Basel). 2010;220:147–153.
4. Hessam S, Sand M, Bechara FG., When inflammation shifts to malignancy: extensive squamous cell carcinoma in a female hidradenitis suppurativa/acne inversa patient. J Dtsch Dermatol Ges. 2017;15:86–88.
5. Kundu JK, Surh YJ., Inflammation: gearing the journey to cancer. Mutat Res. 2008;659:15–30.
6. Turculeanu A, Mogoantă CA, IoniŢă E, et al. TNF-α evaluation in tonsil cancer. Rom J Morphol Embryol. 2015;56:101–106.
7. Zitelli KB, Zedek D, Ranganathan P, et al. Squamous cell carcinoma of the lip associated with adalimumab therapy for ankylosing spondylitis: a case report and review of TNF-α inhibitors and cutaneous carcinoma risk. Cutis. 2013;92:35–39.
8. Scheinfeld N., A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma. Dermatol Online J. 2014;20:3.
9. Ruocco V, Brunetti G, Puca RV, et al. The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites. J Eur Acad Dermatol Venereol. 2009;23:1364–1373.
10. Ruocco V, Ruocco E, Piccolo V, et al. The immunocompromised district in dermatology: a unifying pathogenic view of the regional immune dysregulation. Clin Dermatol. 2014;32:569–576.
11. Baroni A, Buommino E, De Gregorio V, et al. Structure and function of the epidermis related to barrier properties. Clin Dermatol. 2012;30:257–262.
12. Ruocco V, Schwartz RA, Ruocco E., Lymphedema: an immunologically vulnerable site for development of neoplasms. J Am Acad Dermatol. 2002;47:124–127.
13. Faye O, Petit F, Poli F, et al. Lymphedema as a complication of hidradenitis suppurativa in three patients. Ann Dermatol Venereol. 2007;134:567–569.
14. Moosbrugger EA, Mutasim DF., Hidradenitis suppurativa complicated by severe lymphedema and lymphangiectasias. J Am Acad Dermatol. 2011;64:1223–1224.
15. Menter A., Recognizing and managing comorbidities and complications in hidradenitis suppurativa. Semin Cutan Med Surg. 2014;33:S54–S56.
16. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology. 2003;36:84–91.
17. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Consensus document of the International Society of Lymphology. Lymphology. 2009;42:51–60.
18. Carlson JA., Lymphedema and subclinical lymphostasis (microlymphedema) facilitate cutaneous infections, inflammatory dermatoses, and neoplasia: a locus minoris resistentiae. Clin Dermatol. 2014;32:599–615.
19. Piccolo V, Baroni A, Russo T, et al. Ruocco’s immunocompromised cutaneous district. Int J Dermatol. 2016;55:135–141.